Advertisement

Topics

Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting

09:53 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that preliminary results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chroni...

Other Sources for this Article

LHA Investor Relations
Miriam Weber Miller, 212-838-3777
mmiller@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...